The company also received a second Notice of Allowance relating to the methods of obtaining clinically safe outputs from the system. The allowed claims cover methods of testing the Celution output for contaminants like lipids, red blood cells, enzymes, aggregates and endotoxins.

The company’s patent portfolio has 14 issued US and international patents including a US Patent No. 7,514,075 (the ‘075 patent), which Cytori received on April 7, 2009. Key claims cover multiple additives and reagents which are critical for optimizing intravascular delivery of the Celution System output for indications such as liver disease, cardiovascular disease and renal failure.